Imatinib (Glivec®) in chronic myeloid leukemia (CML)

Reading time less than 1 minute Published: Publication type:

SBU Assessment

Presents a comprehensive, systematic assessment of available scientific evidence for effects on health, social welfare or disability. Full assessments include economic, social and ethical impact analyses. Experts participate in the work. and the reports are reviewed by independent experts.

Contact SBU
Published:
Page published
To top